Mitochondrial & Metabolic
Overview
Peptides that target mitochondrial function and metabolism — mitochondrial-derived peptides (MOTS-c, Humanin), the cardiolipin-targeting tetrapeptide SS-31, the lipolytic hGH fragment AOD-9604 and a comparison page.
| Compound | Class | Mechanism | Primary research targets |
|---|---|---|---|
| MOTS-c | Mitochondrial-derived peptide | AMPK / SIRT1, exercise mimetic | Insulin sensitivity, exercise, aging |
| SS-31 (Elamipretide) | Cardiolipin-targeting tetrapeptide | Cardiolipin binding, ETC support | Mitochondrial function, ischemia |
| Humanin | Mitochondrial-derived peptide | Bax/Bid inhibition, cytoprotection | Neuroprotection, longevity |
| AOD-9604 | Modified hGH fragment | Adipocyte β-adrenergic lipolysis | Lipolysis, cartilage repair |
How Mitochondrial Peptides Work
This category targets mitochondrial and metabolic biology from different angles. Mitochondrial-derived peptides (MOTS-c, Humanin) are encoded within mitochondrial DNA and act as stress-responsive regulators — MOTS-c on AMPK and metabolism, Humanin on anti-apoptotic cytoprotection. SS-31 (elamipretide) binds cardiolipin to stabilise the inner mitochondrial membrane and electron transport. AOD-9604 is a growth-hormone C-terminal fragment studied for fat metabolism without the GH / IGF-1 axis.
1. Mitochondrial biogenesis & dynamics
MOTS-c via AMPK/SIRT1; SS-31 stabilises cardiolipin and electron transport; Humanin maintains membrane potential.
2. Energy metabolism
MOTS-c promotes glucose uptake and fatty-acid oxidation; AOD-9604 stimulates lipolysis; SS-31 improves ATP efficiency.
3. Cellular stress & cytoprotection
Humanin is anti-apoptotic (Bax/Bid); SS-31 scavenges superoxide and blocks the permeability-transition pore; MOTS-c activates the UPRmt.
4. Metabolic-hormone signalling
MOTS-c acts as an exercise mimetic (FGF21, METRNL); AOD-9604 targets adipocyte β-adrenergic receptors.
Key Properties at a Glance
| Compound | CAS number | MW (Da) | Length | Mechanism | Half-life |
|---|---|---|---|---|---|
| MOTS-c | 1626405-30-4 | ≈ 2174.6 | 16 aa | AMPK / SIRT1, exercise mimetic | ~ 2–4 h |
| SS-31 (Elamipretide) | 736992-21-5 | 639.81 | 4 aa | Cardiolipin binding, ETC support | ~ 2–4 h |
| Humanin | 330936-65-3 | ≈ 2687.2 | 24 aa | Bax/Bid inhibition, cytoprotection | ~ 1–3 h |
| AOD-9604 | 221231-10-3 | ≈ 1815.1 | 16 aa | Adipocyte β-adrenergic lipolysis | ~ 2–4 h |
Research Evidence Summary
Representative reported findings from the literature (qualitative). See each compound page for detail.
| Compound | Key reported finding | Reference |
|---|---|---|
| MOTS-c | Improved insulin sensitivity and glucose tolerance | Lee C et al., 2015 |
| MOTS-c | Enhanced exercise capacity in aged animals | Reynolds JC et al., 2020 |
| MOTS-c | AMPK-mediated metabolic (exercise-mimetic) effects | MOTS-c literature |
| SS-31 | Improved mitochondrial respiration; reduced oxidative stress | Siegel MP et al. |
| SS-31 | Reduced ischemia–reperfusion injury | Szeto HH; Birk AV et al. |
| SS-31 | Clinical-stage in primary mitochondrial myopathy | Stealth BioTherapeutics |
| Humanin | Protection against amyloid-β toxicity | Hashimoto Y et al., 2001 |
| Humanin | Improved insulin sensitivity | Muzumdar RH et al. |
| Humanin | Cytoprotection via Bax/Bid inhibition | Humanin literature |
| AOD-9604 | Stimulated lipolysis without GH-receptor activation | Ng FM et al. |
| AOD-9604 | Reduced body fat without glucose or IGF-1 effects | preclinical literature |
| AOD-9604 | Enhanced chondrocyte proteoglycan synthesis | preclinical literature |
Research Dosing Overview
Typical research dose ranges from the literature (for research reference only, not human dosing guidance):
| Compound | Research dose | Route | Frequency | Duration |
|---|---|---|---|---|
| MOTS-c | 5–15 mg | SC / IP | 1–2×/wk | 4–12 wk |
| SS-31 (Elamipretide) | 0.5–2 mg | SC / IV | Daily | 2–8 wk |
| Humanin | 2–8 mg | SC / IV | 1–2×/day | 4–12 wk |
| AOD-9604 | 300–1000 µg | SC | Daily | 4–12 wk |
Formulation & Reconstitution
| Factor | Recommendation |
|---|---|
| Solvent | Bacteriostatic water (0.9% benzyl alcohol) |
| Reconstitution | 1–2 mL per vial (peptide-dependent) |
| Storage (lyophilized) | −20°C, desiccated, protected from light |
| Storage (reconstituted) | 2–8°C for up to 7–14 days |
| pH stability range | 5.0–7.0 |
| Oxidation-sensitive residues | Protect Met / Cys peptides from air and light; add antioxidant where relevant |
Selected References
- Lee C, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis. Cell Metabolism, 2015.
- Reynolds JC, et al. MOTS-c is an exercise-induced regulator of physical decline. Nature Communications, 2020.
- Hashimoto Y, et al. Humanin, a neuroprotective rescue factor. Proceedings of the National Academy of Sciences, 2001.
- Szeto HH. Cardiolipin-targeting peptides (SS-31 / elamipretide) research literature.
Need research-grade peptides?
HPLC-verified, COA per batch. Tell us the quantity you need.
